IRulya Therapeutics Inc.
IRLANext catalyst
Dexamethasone sodium phosphate
Ataxia Telangiectasia
Get an email about IRLA's next catalysts
Track IRulya Therapeutics (IRLA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout, earnings).See the timeline
3 upcoming, 0 past
Dexamethasone sodium phosphate Phase 3 Est. Readout
Primary completion for Dexamethasone sodium phosphate trial (NCT06664853) in Ataxia Telangiectasia
SourceLAM-001 Phase 2 Est. Readout (INSPO-BOS)
Estimated primary completion for LAM-001 trial (NCT06018766) in Bronchiolitis Obliterans Syndrome. Topline data typically follows completion by weeks to months.
SourceIRLA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.83 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
EryDex Low dose DSP
Nervous System Disease
Dexamethasone sodium phosphate
Ataxia Telangiectasia
Dex 21-P
Ulcerative Colitis
Apilimod Dimesylate Capsule
COVID-19 Disease
LAM-001
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
LAM-002A
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EryDex Low dose DSP | Phase 3 | Nervous System Disease | - | - |
Dexamethasone sodium phosphate | Phase 3 | Ataxia Telangiectasia | - | - |
Dex 21-P | Phase 2 | Ulcerative Colitis | - | - |
Apilimod Dimesylate Capsule | Phase 2 | COVID-19 Disease | - | - |
LAM-001 | Phase 2 | Pulmonary Hypertension Due to Lung Diseases and Hypoxia | - | - |
LAM-002A | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in IRulya Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in IRulya Therapeutics Inc.'s (IRLA) pipeline across Phase 3, Phase 2. Its lead program is Dexamethasone sodium phosphate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IRulya Therapeutics Inc.'s next FDA catalyst?→
IRulya Therapeutics Inc.'s (IRLA) next tracked catalyst is a Phase 3 readout expected Q4 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IRLA biotech catalysts?→
Add IRLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IRulya Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
